Article
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
Blood - 14 Jul 2011
Wang Jinyong, Liu Yangang, Li Zeyang, Wang Zhongde, Tan Li Xuan, Ryu Myung-Jeom, Meline Benjamin, Du Juan, Young Ken H, Ranheim Erik, Chang Qiang, Zhang Jing
Abstract excerpt
Both monoallelic and biallelic oncogenic NRAS mutations are identified in human leukemias, suggesting a dose-dependent role of oncogenic NRAS in leukemogenesis. Here, we use a hypomorphic oncogenic Nras allele and a normal oncogenic Nras allele (Nras G12D(hypo) and Nras G12D, respectively) to create a gene dose gradient ranging from 25% to 200% of endogenous Nras G12D/+. Mice expressing Nras G12D(hypo)/G12D(hypo)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.